

# The Value of Transbronchial Lung Biopsy in the Diagnosis of Lymphangiomyomatosis

wenshuai xu

Peking Union Medical College Hospital

han cui

Chinese Academy of Medical Sciences & Peking Union Medical College

hongrui Liu

Peking Union Medical College Hospital

ruie feng

Peking Union Medical College Hospital

Xinlun Tian

Peking Union Medical College Hospital

Yanli Yang

Peking Union Medical College Hospital

kaifeng Xu (✉ [xukf@pumch.cn](mailto:xukf@pumch.cn))

Peking Union Medical College Hospital

---

## Research Article

**Keywords:** Lymphangiomyomatosis, biopsy, transbronchial lung biopsy, pathology, diagnosis

**Posted Date:** December 16th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-121160/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**BACKGROUND:** Transbronchial lung biopsy (TBLB) in the diagnosis of lymphangioleiomyomatosis (LAM) is not a common approach, although TBLB is often performed in diffuse lung diseases. We aimed to examine the diagnostic value and safety of TBLB in LAM patients based on the data collected in our center.

**METHODS:** We reviewed LAM patients registered with the LAM Clinic in our hospital from December 8, 2006, to December 30, 2019. All patients with definite or probable diagnosis of LAM who had been examined using TBLB were included. All available pathology slides were reviewed by an experienced LAM pathologist. All complications were reviewed by the medical record and confirmed using telephone interviews.

**RESULTS:** The pathology results of 86 patients (including 74 definite LAM and 12 probable LAM) were available. The positive rate of TBLB in LAM patients was 49/86 (57.0%). The positive rates of SMA, HMB-45, ER, and PR in LAM patients were 97.6%, 93%, 84.6%, and 78.4%, respectively. The positive rate of TBLB was 40%, 60% and 60.8% in mild, moderate, or severe LAM patients, respectively, and the difference was not significant. Patients who had 3-4 or 5-6 biopsied specimens had a higher rate of diagnosis than those with 1-2 biopsied specimens. Four patients (5.6%) reported pneumothorax. No major hemoptysis was reported.

**CONCLUSIONS:** TBLB is a feasible and safe procedure for obtaining a pathological diagnosis of LAM. Taking more than 2 samples during the biopsy procedure increased the rate of diagnosis.

## 1. Introduction

Lymphangioleiomyomatosis (LAM) is a rare disease that predominantly affects females with clinical features of progressive cystic destruction of the lungs and the accumulation of LAM cells within the lungs and axial lymphatics(1). Sporadic LAM affects 1 in 400,000 adult females, while it is common in adult females with tuberous sclerosis complex (TSC) (2). The diagnostic criteria of definite LAM include characteristic or compatible features on high resolution CT of the chest and lung biopsy fitting the pathological criteria for LAM or characteristic HRCT features and any of the following: renal angiomyolipoma, thoracic or abdominal chylous effusion, lymphangioleiomyoma or lymph node involvement by LAM, TSC or elevation of vascular endothelial growth factor-D (VEGF-D) in serum(2, 3). In addition, there are many conditions that can mimic lung cysts and cause cystic lung disease, such as Langerhans cell histiocytosis, lymphoid interstitial pneumonia, and Birt-Hogg-Dubé syndrome(4). Lung biopsy is important for the diagnosis of LAM. Transbronchial lung biopsy (TBLB) is less invasive than surgical lung biopsy. Current guidelines for LAM recommend TBLB before surgical lung biopsy(3). However, the experience of this application has seldom been reported since the publication of this recommendation(5, 6). We aimed to report our experience using TBLB on patients at the LAM Clinic in Peking Union Medical College Hospital (PUMCH), Beijing, China.

## 2. Materials And Methods

We reviewed LAM patients registered with the LAM center in PUMCH from December 8, 2006, to December 30, 2019, in our database to determine which patients had undergone TBLB. All patients with a definite diagnosis of LAM or probable diagnosis of LAM who had been examined by TBLB were included. The diagnosis criteria of definite LAM were based on ATS/JRS guidelines(3). The diagnosis criteria of probable LAM were based on ERS guidelines(2). The following data were collected: (1) diagnosis-related information: history of chylous effusion, HRCT of the chest, CT or MRI or ultrasound of abdomen, and serum VEGF-D; (2) number of samples biopsied during bronchoscopy; (3) pathological results including immunohistochemical examination; and (4) complications during bronchoscopy or within 24 hours after the procedure.

Analyses of chest CT scans in these patients were conducted with digital CT images. The thickness of CT slices in most of the patients was high-resolution CT (HRCT), or no more than 5 mm in the remaining patients. The severity of abnormalities was graded according to the percentage of the volume judged abnormal as follows: 0, absent; mild, less than 30% abnormal; moderate, 30–60% abnormal; and severe, more than 60% abnormal(7).

All pathology slides were reviewed by experienced pathologists in LAM. Pathology slides from other hospitals were re-examined by one of our pathologists if the slides were available. Positive TBLB was defined as lung biopsies positive for HMB-45 or negative for HMB-45 biopsy showing typical LAM cell infiltration in hematoxylin and eosin-stained histological sections.

All complications were reviewed using medical records and confirmed using telephone interviews. Complication of moderate or severe hemoptysis was defined as hemoptysis that was persistent or required treatment. Pneumothorax was defined as a clinical manifestation of pneumothorax and confirmed by X-ray within 24 hours of the procedure.

## 3. Statistical Method

Data were analyzed using SPSS for Windows version 24.0 (IBM Corp., USA) and are reported as the mean (SD). The *unpaired t-test* was used to compare continuous variables. Categorical variables were compared using *Pearson's chi-square test*. For all analyses, two-sided tests and a significance level of 0.05 were used.

## 4. Results

### Patient Information

Figure 1 shows the flowchart of the study. In detail, 687 LAM patients registered in PUMCH were reviewed, including 587 definite LAM patients and 100 probable LAM patients. The database recorded 86 of the 687 patients who had a history of TBLB, including 74 definite LAM patients and 12 probable LAM

patients. Among 86 patients, 52 underwent TBLB in PUMCH, while 34 underwent TBLB in other hospitals. Six of 34 patients who underwent TBLB not in our hospital had pathological slides reviewed, 4 negative and 2 positive results. One of the 6 patients had the diagnosis revised from negative to positive after pathological slide review.

## **Pathological diagnosis of LAM from TBLB samples**

In total, the positive rate of TBLB for LAM diagnosis was 49/86 (57.0%). The positive rate of TBLB performed in PUMCH was 31/52 (59.6%). The positive rate of TBLB performed in other hospitals was 18/34 (52.9%).

For patients with negative TBLB, 20/37 (54%) patients did not have immunohistochemistry testing performed on their samples because there were no typical LAM cell infiltrations in hematoxylin and eosin-stained histological sections. Therefore, we only calculated the immunohistochemistry in the positive TBLB patients. The positive rate of smooth muscle actin (SMA) in patients with positive TBLB was 40/41 (97.6%). The positive rate of HMB-45 in patients with positive TBLB was 40/43 (93%). The positive yields of estrogen receptor (ER) and progesterone receptor (PR) were 33/39 (84.6%) and 29/37 (78.4%), respectively (Fig. 2A;Table 1).

Table 1  
Characteristics comparison between positive TBLB and negative TBLB patients

Characteristics	Total TBLB N = 86	Positive TBLB N = 49	Negative TBLB N = 37	P value
Age, mean ± SD	42 ± 9	42 ± 9	41 ± 8	0.554¶
Definite LAM, N (%)	74 (86.0)	49 (100)	25 (67.6)	< 0.001
AML, N (%)	11 (12.8)	7 (14.3)	4 (10.8)	0.879
Chylothorax, N (%)	9 (10.5)	6 (12.2)	3 (8.1)	0.791
Chylous ascites, N (%)	1 (1.2)	1 (2.0)	0 (0)	1.000
Lymphangiomyoma, n/N (%)	26/77 (33.8)	16 (36.4)	10 (30.3)	0.574
VEGF-D > 800, n/N (%)	57/76 (75.0)	36/43 (83.7)	21/33 (63.6)	0.045
CT grade	n = 76	n = 43	n = 33	
I, N (%)	15 (19.7)	6 (14.0)	9 (27.3)	0.147
II, N (%)	10 (13.2)	6 (14.0)	4 (12.1)	1.000
III, N (%)	51 (67.1)	31 (72.0)	20 (60.6)	0.291
NO. of biopsy specimens	n = 61	n = 37	n = 24	
1–2 specimens, N (%)	7 (11.5)	1 (2.7)	6 (25.0)	0.024
3–4 specimens, N (%)	46 (75.4)	29 (78.4)	17 (70.8)	0.504
5–6 specimens, N (%)	8 (13.1)	7 (18.9)	1 (4.2)	0.201
Immunohistochemical				
SMA, n/N (%)	53/57 (93.0)	40/41 (97.6)	13/16 (81.25)	0.112
HMB-45, n/N (%)	40/60 (66.7)	40/43 (93.0)	0/17 (0)	< 0.001
ER, n/N (%)	38/50 (76)	33/39 (84.6)	5/11 (45.5)	0.022
PR, n/N (%)	34/48 (70.8)	29/37 (78.4)	5/11 (45.5)	0.083
The P value was calculated using <i>Pearson's chi-square test</i> .				
¶The P value was calculated with the use of the <i>unpaired t-test</i> .				
Abbreviations: AML: angiomyolipoma; CT: computed tomography; ER: estrogen receptor; PR: progesterone receptor; SMA: smooth muscle actin; TBLB: transbronchial lung biopsy; VEGF-D: vascular endothelial growth factor-D.				

# No difference in diagnostic yield in patients with different degrees of severity

Seventy-six of 86 LAM patients had available CT scans for analysis. The positive rate of TBLB was 6/15 (40%) in mild LAM patients, 6/10 (60%) in moderate LAM patients, and 31/51 (60.8%) in severe LAM patients. However, there was no significant difference in the positive rate between mild, moderate, and severe LAM patients (mild vs moderate,  $p = 0.428$ ; mild vs severe,  $p = 0.154$ ; moderate vs severe,  $p = 1.000$ ) (Fig. 2B).

# Number of biopsy specimens influence the diagnostic yield

Sixty-one of the 86 reports recorded the number of biopsy specimens. Seven patients had 1–2 specimens taken, and the positive rate was only 1/7 (14.3%). Thirty-nine patients were 3–4 specimens taken, and the positive rate was 29/46 (63.0%). Seven patients had 5–6 specimens taken, and the positive rate was 7/8 (87.5%). There were significant differences in positive rates between LAM patients with 1–2 specimens and patients with 3–4 specimens ( $p = 0.044$ ). However, there was no significant difference between patients with 3–4 specimens and patients with 5–6 specimens ( $p = 0.154$ ) (Fig. 2C).

# Complications of TBLB in LAM

Seventy-one of the 86 patients replied to the telephone questionnaire of the complications after the TBLB procedure. Four patients (5.6%) reported pneumothorax. No major hemoptysis was reported. No other complications, such as pulmonary infections, were found.

## 5. Discussion

Diagnostic yield was favorable for TBLB in the diagnosis of LAM with varying degrees of lung involvement. The major finding of this work is a 57% positive rate of diagnosis and 5.6% TBLB-related pneumothorax. The positive rate was different between patients who had 1–2 biopsied samples and 3 or more.

Pathology is essential for LAM patients who cannot be definitely diagnosed based on the clinical presentations, VEGF-D, and radiological appearance. In 1991, Pedreira et al. first reported that TBLB was used in the diagnosis of LAM(8). In 1993, Bonetti et al recommended that HMB45 should be used to distinguish LAM from other smooth muscle proliferation; the positive rate of HMB-45 in LAM was 92%, and the histological diagnosis of LAM could be made when only a transbronchial biopsy is available(9). In 2012, Torre and Harari reported that TBLB was performed in seven patients and was diagnostic in six and did not result in complications(10). Meraj *et al.* found that TBLB was positive in 6 of 10 patients and had a yield of approximately 60% in LAM, with 52/217 (14%) complications, including pneumothorax (6%), bleeding (4%), chest pain (2%) and pneumonia (2%)(11). In recent years, some researchers reported

that the positive rate of TBLB in patients with LAM was 70–78%, and there were no serious adverse events such as pneumothorax or uncontrollable bleeding due to TBLB(5, 6). Our results offered similar experience of the value of TBLB in LAM. The positive rate of TBLB in our results was similar to those previously reported(5, 6, 12). In addition, the complications of TBLB were also similar to previous reports. It was reported that the severity of LAM in CT scans will affect the positive rate of TBLB, but in our results, there was no difference in diagnostic yield in patients with different degrees of severity, although the trend existed(6). We first found that the number of biopsy specimens influenced the positive diagnosis rate. We recommended that at least 3 samples should be biopsied during TBLB.

Immunostaining with HMB-45 antibody is considered to be the most reliable method for the specific identification of LAM cells(13). In our study, the positive yield of HMB-45 in the diagnostic biopsies was 93%, which is similar to the previously reported rate of 92%(9). HMB-45 was not positive in all LAM cells, but it was a valuable marker in LAM(14). Gao et al reported that in LAM, the expression of progesterone receptor is frequently higher than that of estrogen receptor(14). However, our pathological reports showed that the positive yields of estrogen receptor (ER) and progesterone receptor (PR) were quite similar (84% and 78%, respectively). In patients with LAM, the severity of LAM in CT scans will affect the positive rate of TBLB(6). In our reports, mild LAM patients had a lower positive rate than moderate/severe LAM patients. However, there was no significant difference between mild, moderate, and severe LAM patients. This may result in a limited number of patients, especially few mild and moderate LAM patients. We found that with the increasing number of specimens, the positive rate will improve. Increasing the number of specimens did not increase the risk of complications in our reports. We recommended that the minimum number of samples biopsied should be three or more unless complications occur during the procedure.

Four patients (5.6%) reported pneumothorax, and no one reported major hemorrhage. Previous reports of TBLB in LAM found 0%-6% pneumothorax and 0%-4% hemorrhage(5, 6, 12).

De Fenoyl et al. reported that pneumothorax occurred in 3.4% of patients with interstitial lung disease who underwent TBLB(15). The complication of pneumothorax in LAM may be slightly higher than in patients with interstitial lung disease. Evaluation before, during and after the procedure is critical in the early finding of pneumothorax. Large bulli should be avoided during the procedure.

TBLB is effective and safe for patients with LAM; however, some patients cannot be diagnosed with TBLB. Recently, transbronchial cryobiopsy (cryo-TBB) has been introduced as a technique to obtain biopsy samples of lung parenchyma that exceed the size and quality of forceps biopsy samples(16–18). Cryo-TBB yields larger biopsy specimens (43 to 64 mm<sup>2</sup>) than transbronchial biopsy (5.8 mm<sup>2</sup>, range 0.58 to 20.88 mm<sup>2</sup>)(16, 19, 20). Cryo-TBB in patients with central, peribronchial or diffuse interstitial processes is now used clinically. The major complications of cryo-TBB included pneumothorax (12 to 28%), moderate bleeding (0 to 39%), and rarely death (0.3%)(17, 18, 20). However, there is no evidence of LAM in using cryo-TBB for diagnosis. Pneumothorax risk is a major concern of cryo-TBB in LAM patients.

There are some limitations to this study. First, it involved a small group of mild and moderate patients; therefore, we do not clearly know whether the severity of CT grades will influence the positive rate of TBLB. Second, how to evaluate the risk of pneumothorax or hemorrhage before the TBLB procedure has not been investigated.

## 6. Conclusion

We concluded that TBLB was a favorable and safe diagnostic procedure for LAM. An increasing number of specimens may improve the positive rate. The complication of pneumothorax was low. We support the ATS/JRS guidelines that recommended TBLB should be considered before surgical lung biopsy is considered(3).

## Declarations

## Ethics approval and consent to participate

All methods of this study were carried out in accordance with relevant guidelines and regulation. The study was part of LAM registry study of Peking Union Medical College Hospital. The protocol of this study was approved by the Ethical Committee of Peking Union Medical College Hospital [S-k1244]. All subjects included in this study signed informed consent documents.

## Consent for publication

Consent for publication was obtained from all participants.

## Availability of data and materials

The datasets used and analyzed in current study available from the corresponding author.

## Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Authors contributions

Wenshuai Xu: date collection, data analysis and manuscript writing.

Han Cui: date collection, data analysis.

Hongrui Liu: pathology review.

Ruie Feng: pathology review.

Xinlun Tian: data collection.

Yanli Yang: study design, data collection, data analysis.

Kai-Feng Xu: study design, data collection, data analysis, manuscript writing.

## Funding

The National Key Research and Development Program of China (2016YFC0901502)

CAMS Innovation Fund for Medical Sciences (CIFMS) (2017-I2M-2-001)

## Acknowledgements


We thank all the patients for their contribution to this work.

## References

1. Johnson SR. Lymphangiomyomatosis. *The European respiratory journal*. 2006;27(5):1056-65.
2. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangiomyomatosis. *The European respiratory journal*. 2010;35(1):14-26.
3. Gupta N. Lymphangiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. 2017;196(10):1337-48.
4. Koo HK, Yoo CG. Multiple cystic lung disease. *Tuberculosis and respiratory diseases*. 2013;74(3):97-103.
5. Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, Taveira-DaSilva AM, et al. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangiomyomatosis: A report of 24 consecutive patients. *Am J Respir Crit Care Med*. 2018;23(3):331-8.
6. Okamoto S, Suzuki K, Hayashi T, Muraki K, Nagaoka T, Nishino K, et al. Transbronchial lung biopsy for the diagnosis of lymphangiomyomatosis: the severity of cystic lung destruction assessed by the modified Goddard scoring system as a predictor for establishing the diagnosis. *Orphanet journal of rare diseases*. 2020;15(1):125.


7. Avila NA, Chen CC, Chu SC, Wu M, Jones EC, Neumann RD, et al. Pulmonary lymphangiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. *Radiology*. 2000;214(2):441-6.
8. Díaz Pedreira JA, González-Carreró J, Cameselle Veloso R, Barros Tizón JC, Bandrés Gimeno R. [Pulmonary lymphangiomyomatosis. Presentation of a new case]. *Anales de medicina interna (Madrid, Spain : 1984)*. 1991;8(12):614-6.
9. Bonetti F, Chiodera PL, Pea M, Martignoni G, Bosi F, Zamboni G, et al. Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis. *The American journal of surgical pathology*. 1993;17(11):1092-102.
10. Harari S, Torre O, Cassandro R, Taveira-DaSilva AM, Moss J. Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangiomyomatosis. *Respiratory medicine*. 2012;106(9):1286-92.
11. Meraj R, Wikenheiser-Brokamp KA, Young LR, Byrnes S, McCormack FX. Utility of transbronchial biopsy in the diagnosis of lymphangiomyomatosis. *Frontiers of medicine*. 2012;6(4):395-405.
12. Meraj R, Wikenheiser-Brokamp KA, Young LR, Byrnes S, McCormack FX. Utility of transbronchial biopsy in the diagnosis of lymphangiomyomatosis. *Respirology (Carlton, Vic)*. 2012;6(4):395-405.
13. Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA, et al. Lymphangiomyomatosis (LAM): a review of clinical and morphological features. *Journal of Nippon Medical School = Nippon Ika Daigaku zasshi*. 2000;67(5):311-29.
14. Gao L, Yue MM, Davis J, Hyjek E, Schuger L. In pulmonary lymphangiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. *Virchows Archiv : an international journal of pathology*. 2014;464(4):495-503.
15. de Fenoyl O, Capron F, Lebeau B, Rochemaure J. Transbronchial biopsy without fluoroscopy: a five year experience in outpatients. *Thorax*. 1989;44(11):956-9.
16. Babiak A, Hetzel J, Krishna G, Fritz P, Moeller P, Balli T, et al. Transbronchial cryobiopsy: a new tool for lung biopsies. *Respiration; international review of thoracic diseases*. 2009;78(2):203-8.
17. Ravaglia C, Bonifazi M, Wells AU, Tomassetti S, Gurioli C, Piciocchi S, et al. Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases: A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature. *Respiration; international review of thoracic diseases*. 2016;91(3):215-27.
18. Johannson KA, Marcoux VS, Ronksley PE, Ryerson CJ. Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease. A Systematic Review and Metaanalysis. *Ann Am Thorac Soc*. 2016;13(10):1828-38.
19. Fruchter O, Fridel L, El Raouf BA, Abdel-Rahman N, Rosengarten D, Kramer MR. Histological diagnosis of interstitial lung diseases by cryo-transbronchial biopsy. *Respirology (Carlton, Vic)*. 2014;19(5):683-8.
20. Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. *PLoS One*. 2014;9(2):e86716.

# Figures



**Figure 1**

The flowchart of patient selection



**Figure 2**

Pathological diagnosis of LAM from TBLB samples A: Positive rate of immunohistochemistry in positive TBLB patients. B: Positive rate of TBLB in different CT grades of LAM patients. C: Positive rate of TBLB in different numbers of lung biopsy specimens. Abbreviations: CT: computed tomography; TBLB: ER: estrogen receptor; PR: progesterone receptor; SMA: smooth muscle actin; TBLB: transbronchial lung biopsy.